CRISPR Therapeutics AG, a gene-editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 gene-editing platform in Switzerland. The crsp stock news at https://www.webull.com/quote/nasdaq-crsp has details regarding updates on the stock. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta-thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies.
Besides, it is developing allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70, CTX120, a CAR-T cell product candidate for the treatment of multiple myeloma, CTX130 for the treatment of solid tumors and hematologic malignancies programs to treat Hurler Syndrome and severe combined immunodeficiency disease, as well as glycogen storage disease Ia, and programs targeting diseases, such as Duchenne muscular dystrophy and cystic fibrosis. It has collaboration agreements with Vertex Pharmaceuticals, Incorporated and Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use various therapeutics; and Stride Bio LLC to develop adeno-associated viral capsids.
CRISPR Therapeutics AG nasdaqcrsp posted its quarterly earnings data on Wednesday, February, 12th. The company reported $0.51 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.68) by $1.19. The business earned $77 million during the quarter, compared to analyst estimates of $39.08 million. Crispr Therapeutics had a net margin of 23.09% and a return on equity of 11.74%. The firm’s revenue was up 76900.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.92) EPS. CRISPR Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 4th, 2020.
According to Zacks Investment Research, “CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. “
Media coverage about CRSP stock has been trending somewhat negative this week, Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blogs and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Crispr Therapeutics earned a media sentiment score of -1.0 on scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the next few days. You can also know stock news at https://www.webull.com/quote/nysearca-uvxy .